

SUPPLEMENTARY MATERIAL

Appendix 1. Members of the Register of Severe Asthma of the Region of Murcia Group

Registro de Asma GRAve de la Región de MURcia (RE-ASGRAMUR)

Steering Group

Manuel Castilla Martínez (Hospital Universitario Los Arcos del Mar Menor. San Javier),
Juan Carlos Miralles López (Hospital Universitario Reina Sofía. Murcia), José Valverde
Molina (Hospital General Universitario Santa Lucía. Cartagena)

Investigators (alphabetical order of centers)

Manuel Castilla Martínez, Lelia Gacías Pedrós, José Valverde Molina, Andres Barrios
Recio (Hospital Universitario Los Arcos del Mar Menor. San Javier), Loreto Alemany
Francés, Roberto Bernabeu Mora, Ana Mora González (Hospital General Universitario
Morales Meseguer. Murcia), Miguel Henrique Reyes Cotes, Isabel M. Flores Martín
(Hospital Comarcal del Noroeste. Caravaca), El Molaka Zouhair, Inmaculada Ibarra
Calabuig (Hospital General Universitario Rafael Méndez. Lorca), Juan Carlos Miralles
López, María Jesús Avilés Inglés, Consuelo Alcalde Rumayor (Hospital General
Universitario Reina Sofía. Murcia), Javier Bravo Gutiérrez, Rocío Ibáñez Meléndez,
Sheila Cabrejos Perotti, Mercedes Ramírez Hernández, Carolina Díaz García, Francisco
Javier Rodriguez Dominguez (Hospital General Universitario Santa Lucía. Cartagena),

Manuel José Pajarón Fernández, Cayetano Díaz Chantar, Carmen Alvarez Santacruz (Hospital Comarca La Vega. Cieza), Rubén Andújar Espinosa, José Meseguer Arce, Mariola Navarro Guerrero (Hospital Clínico Universitario Virgen de la Arrixaca. Murcia), Antonio Carbonell Martínez (Centro Médico la Fama, Murcia).

Appendix 2. Methods

The following characteristics were recorded: age, time of evolution of the disease, personal history (comorbidities), type 2 biomarkers, and previous systemic/biological treatments. Disease control was assessed by Asthma Control Test (ACT) and quality of life by the miniAQLQ questionnaire. Lung function was measured according to the SEPAR guidelines, using their reference values. FENO was measured using NioxVero electrochemical analyzer according to standard use technique.

Tezepelumab was prescribed following the approved dosage of 210 mg every 4 weeks. This study was in full agreement with the guidance of the indication for tezepelumab financed by the Spanish Medicines and Medical Products Agency (Agencia Española del Medicamento y Productos Sanitarios, AEMPS), and the monitoring of the treatment effect was conducted according to the regulation.

The presence of atopy was defined by positive skin tests or specific IgE.